Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data.
Level 1 - systematic review of randomized trials
Meta-analysis of clinical trial pharmacokinetic data
PubMed 39557444 · doi:10.1002/ptr.8379
What was done
Authors conducted a systematic review and meta-analysis across five databases (PubMed, Cochrane Library, Scopus, Embase, and ScienceDirect) evaluating the oral bioavailability of single-preparation resveratrol in healthy adults. They extracted mean and standard deviation values for pharmacokinetic parameters, assessed heterogeneity and study inconsistency, and performed meta-regression across 84 oral administration data sets covering nine doses ranging from 25 to 5000 mg.
What was found
Free resveratrol entering the bloodstream increased linearly with oral dose, whereas time to maximum concentration (Tmax) remained unaffected. The overall mean maximum plasma concentration (Cmax) was 31.07 ng/mL, which was comparable to the mean Cmax observed in the medium-dose subgroup of 100 to 500 mg (33.59 ng/mL).
Why it matters
This synthesis provides pooled human pharmacokinetic benchmarks for oral resveratrol, suggesting that moderate doses between 100 and 500 mg achieve plasma concentrations comparable to the overall average while minimizing potential side effects.
Limits
The abstract notes substantial heterogeneity and methodological inconsistencies across included clinical trials. Total participant count, specific formulation differences, metabolite profiles, and clinical efficacy endpoints were not reported in the abstract.
Cited by
- supports Pharmacological studies evaluating resveratrol typically use doses between 50 and 500 milligrams.